Spironolactone, not furosemide, improved insulin resistance in patients with chronic heart failure

被引:21
|
作者
Ogino, Kazuhide [1 ]
Kinugasa, Yoshiharu [2 ]
Kato, Masahiko [2 ]
Yamamoto, Kazuhiro [2 ]
Hisatome, Ichiro [3 ]
Anker, Stefan D. [4 ]
Doehner, Wolfram [5 ]
机构
[1] Tottori Univ Hosp, Div Clin Lab, Yonago, Tottori 6838504, Japan
[2] Tottori Univ, Fac Med, Dept Cardiovasc Med, Yonago, Tottori 683, Japan
[3] Tottori Univ, Grad Sch Med, Dept Genet Med & Regenerat Therapeut, Yonago, Tottori 683, Japan
[4] Charite, Campus Virchow Klinikum, Dept Cardiol, Div Appl Cachexia Res, D-13353 Berlin, Germany
[5] Charite, Ctr Stroke Res Berlin, D-13353 Berlin, Germany
关键词
Insulin resistance; Heart failure; Diabetes; Aldosterone; Inflammatory cytokine; Matrix metalloproteinase; ACUTE MYOCARDIAL-INFARCTION; NECROSIS-FACTOR-ALPHA; II RECEPTOR BLOCKER; PRIMARY ALDOSTERONISM; HYPERTENSIVE PATIENTS; HEPATIC STEATOSIS; OXIDATIVE STRESS; ADIPOSE-TISSUE; FOLLOW-UP; INFLAMMATION;
D O I
10.1016/j.ijcard.2013.12.039
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/objectives: Insulin resistance plays an important role in the pathophysiology in chronic heart failure (CHF). Diuretics generally have harmful effects on glucose metabolism, however, the effect of mineral corticoid receptor blockers on insulin resistance in CHF is unclear. This study aimed to evaluate the effects of the aldosterone blocker spironolactone, in comparison with furosemide, on insulin resistance in CHF patients. Methods: The effect of spironolactone (25 mg/day) and furosemide (20 mg/day) on IR for 16 weeks each was analyzed in 16 CHF patients using a double-blind, placebo-controlled, randomized cross-over study design. Results: Plasma BNP and left ventricular ejection fraction were improved with both treatments (furosemide: p = 0.02 and p = 0.009, respectively, spironolactone: p = 0.03 and p = 0.007, respectively). Fasting plasma glucose was not changed; however, plasma insulin levels decreased and insulin sensitivity (by homeostasis model assessment: HOMA-IR) improved with spironolactone as compared to furosemide (p < 0.0005). TNF-alpha, IL-6 and MCP-1 decreased with spironolactone (p = 0.002, p = 0.02 and p = 0.02 vs. baseline, respectively), but not with furosemide. Matrix metalloproteinase (MMP)-2 and MMP-9 were decreased with spironolactone (p = 0.003 and p = 0.04 vs. baseline, respectively), but not furosemide. Changes in TNF-a, IL-6 and MCP-1 levels after spironolactone treatment were significantly correlated with changes in HOMA-IR (r = 0.61, r = 0.55 and r = 0.65, respectively; p = 0.01, p = 0.03 and p = 0.01, respectively). Furthermore, changes in MMP-2 and MMP-9 levels were significantly correlated with changes in HOMA-IR (r = 0.58 and r = 0.58, respectively; p = 0.02 and p = 0.02, respectively). Conclusions: Spironolactone, not furosemide, improved insulin resistance in CHF patients probably by the inhibition of inflammatory cytokines and MMPs. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 50 条
  • [1] Furosemide and spironolactone doses and hyponatremia in patients with heart failure
    Velat, Ivan
    Busic, Zeljko
    Paic, Marina Juric
    Culic, Viktor
    BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01):
  • [2] Furosemide and spironolactone doses and hyponatremia in patients with heart failure
    Ivan Velat
    Željko Bušić
    Marina Jurić Paić
    Viktor Čulić
    BMC Pharmacology and Toxicology, 21
  • [3] Insulin signalling and resistance in patients with chronic heart failure
    Kemppainen, J
    Tsuchida, H
    Stolen, K
    Karlsson, H
    Björnholm, M
    Heinonen, OJ
    Nuutila, P
    Krook, A
    Knuuti, J
    Zierath, JR
    JOURNAL OF PHYSIOLOGY-LONDON, 2003, 550 (01): : 305 - 315
  • [4] Losartan improved insulin resistance in patients with congestive heart failure
    Ogino, Kazuhide
    Kato, Masahiko
    Furuse, Yoshiyuki
    Ishida, Katsunori
    Yanagihara, Kiyotaka
    Igawa, Osamu
    Hisatome, Ichiro
    Shigemasa, Chiaki
    JOURNAL OF CARDIAC FAILURE, 2006, 12 (08) : S171 - S172
  • [5] Losartan improved insulin resistance and decreased TNF-alpha in patients with chronic heart failure
    Ogino, K.
    Kato, M.
    Furuse, Y.
    Kinugasa, Y.
    Ishida, K.
    Igawa, O.
    Hisatome, I.
    Shigemasa, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2007, 6 : 139 - 139
  • [6] Insulin resistance in chronic heart failure
    Coats, AJS
    Anker, S
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 : S9 - S14
  • [7] Safety of spironolactone in patients with chronic heart failure in Malaysia
    Lau, G. S. K.
    Jagdeep, J. S. S.
    Ross, N. O. E. L. R.
    Yusoff, M. R.
    Ngau, Y. Y. N. G. A. U.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 292 - 292
  • [8] Hyperkalemia and renal dysfunction in congestive heart failure patients with concomitant use of spironolactone and furosemide
    Anzai, N
    Anzai, H
    Mitobe, R
    Anzai, M
    Furuya, S
    CHEST, 2005, 128 (04) : 281S - 281S
  • [9] Insulin resistance in chronic heart failure - Reply
    Witteles, Ronald M.
    Fowler, Michael B.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (03) : 239 - 240
  • [10] Insulin resistance and survival in chronic heart failure
    Doehner, W
    Godsland, IF
    Rauchhaus, M
    Ponikowski, PP
    Coats, AJ
    Anker, SD
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 158A - 158A